Precision-engineering of subunit vaccine particles for prevention of infectious diseases
- PMID: 36817419
- PMCID: PMC9935699
- DOI: 10.3389/fimmu.2023.1131057
Precision-engineering of subunit vaccine particles for prevention of infectious diseases
Abstract
Vaccines remain the best approach for the prevention of infectious diseases. Protein subunit vaccines are safe compared to live-attenuated whole cell vaccines but often show reduced immunogenicity. Subunit vaccines in particulate format show improved vaccine efficacy by inducing strong immune responses leading to protective immunity against the respective pathogens. Antigens with proper conformation and function are often required to induce functional immune responses. Production of such antigens requiring post-translational modifications and/or composed of multiple complex domains in bacterial hosts remains challenging. Here, we discuss strategies to overcome these limitations toward the development of particulate vaccines eliciting desired humoral and cellular immune responses. We also describe innovative concepts of assembling particulate vaccine candidates with complex antigens bearing multiple post-translational modifications. The approaches include non-covalent attachments (e.g. biotin-avidin affinity) and covalent attachments (e.g. SpyCatcher-SpyTag) to attach post-translationally modified antigens to particles.
Keywords: cross-presentation; dendritic cells; infectious diseases; particulate vaccine; post-translational modification; protective immunity.
Copyright © 2023 Chen, Pounraj, Sivakumaran, Kakkanat, Sam, Kabir and Rehm.
Conflict of interest statement
Author BHAR is an inventor of the biopolymer particle technology and co-founder/shareholder of Polybatics Ltd. BHAR and SC are inventors on a patent application describing the immunogenic carrier protein CRM197 vaccine platform and its uses. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Bacterial superglue enables easy development of efficient virus-like particle based vaccines.J Nanobiotechnology. 2016 Apr 27;14:30. doi: 10.1186/s12951-016-0181-1. J Nanobiotechnology. 2016. PMID: 27117585 Free PMC article.
-
Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine.Adv Vet Med. 1999;41:447-61. doi: 10.1016/s0065-3519(99)80034-2. Adv Vet Med. 1999. PMID: 9890035 Review.
-
Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.Biotechnol Adv. 2017 May-Jun;35(3):375-389. doi: 10.1016/j.biotechadv.2017.03.005. Epub 2017 Mar 11. Biotechnol Adv. 2017. PMID: 28288861 Review.
-
Nanoparticle Vaccines Against Infectious Diseases.Front Immunol. 2018 Oct 4;9:2224. doi: 10.3389/fimmu.2018.02224. eCollection 2018. Front Immunol. 2018. PMID: 30337923 Free PMC article. Review.
-
PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.Hum Vaccin Immunother. 2016 Apr 2;12(4):1056-69. doi: 10.1080/21645515.2015.1117714. Epub 2016 Jan 11. Hum Vaccin Immunother. 2016. PMID: 26752261 Free PMC article. Review.
Cited by
-
Changes in intestinal flora of mice induced by rEg.P29 epitope peptide vaccines.Immun Inflamm Dis. 2023 Nov;11(11):e1082. doi: 10.1002/iid3.1082. Immun Inflamm Dis. 2023. PMID: 38018604 Free PMC article.
-
Advances in neoantigen-based immunotherapy for head and neck squamous cell carcinoma: a comprehensive review.Front Oncol. 2025 May 15;15:1593048. doi: 10.3389/fonc.2025.1593048. eCollection 2025. Front Oncol. 2025. PMID: 40444094 Free PMC article. Review.
-
Q fever immunology: the quest for a safe and effective vaccine.NPJ Vaccines. 2023 Sep 7;8(1):133. doi: 10.1038/s41541-023-00727-6. NPJ Vaccines. 2023. PMID: 37679410 Free PMC article. Review.
-
Intranasal Epitope-Polymer Vaccine Lodges Resident Memory T Cells Protecting Against Influenza Virus.Adv Healthc Mater. 2024 Jun;13(15):e2304188. doi: 10.1002/adhm.202304188. Epub 2024 Mar 9. Adv Healthc Mater. 2024. PMID: 38411375 Free PMC article.
-
Introduction of protein vaccine candidate based on AP65, AP33, and α-actinin proteins against Trichomonas vaginalis parasite: an immunoinformatics design.Parasit Vectors. 2024 Mar 31;17(1):165. doi: 10.1186/s13071-024-06248-y. Parasit Vectors. 2024. PMID: 38556882 Free PMC article.
References
-
- Seyfoori A, Shokrollahi Barough M, Mokarram P, Ahmadi M, Mehrbod P, Sheidary A, et al. . Emerging advances of nanotechnology in drug and vaccine delivery against viral associated respiratory infectious diseases (Varid). Int J Mol Sci (2021) 22(13):6937. doi: 10.3390/ijms22136937 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical